Key Insights

Highlights

Success Rate

91% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 30/100

Termination Rate

5.9%

2 terminated out of 34 trials

Success Rate

91.3%

+4.8% vs benchmark

Late-Stage Pipeline

35%

12 trials in Phase 3/4

Results Transparency

24%

5 of 21 completed with results

Key Signals

5 with results91% success

Data Visualizations

Phase Distribution

32Total
Not Applicable (12)
P 1 (2)
P 2 (6)
P 3 (9)
P 4 (3)

Trial Status

Completed21
Recruiting3
Unknown3
Terminated2
Active Not Recruiting2
Withdrawn2

Trial Success Rate

91.3%

Benchmark: 86.5%

Based on 21 completed trials

Clinical Trials (34)

Showing 20 of 20 trials
NCT06138613Phase 3Active Not RecruitingPrimary

Motion Delos: An Open Label Safety and Efficacy of Tradipitant in Participants Affected by Motion Sickness

NCT07297862Enrolling By InvitationPrimary

Virtual Reality Sickness Questionnaire: Psychometrics in Stroke Patients

NCT06106256Not ApplicableActive Not RecruitingPrimary

Three-Axis Wearable Adaptive Vestibular Stimulator

NCT06587386Phase 4CompletedPrimary

The Minimum Effective Dose (ED90) of Liposomal Bupivacaine for Preserving Motor Function

NCT05622344Not ApplicableRecruiting

StableEyes With Active Neurofeedback

NCT04999449Phase 1Completed

Nebulizer Delivery of Intranasal Scopolamine

NCT06892340Not ApplicableRecruitingPrimary

Evaluation of a Device to Reduce Motion Sickness and Spatial Disorientation

NCT06354309Not ApplicableCompleted

Impact of Different Types of Virtual Reality Games on Motion Sickness and Ocular in Adults: A Pilot Study

NCT03772340Phase 2CompletedPrimary

Motion Sifnos: A Study to Investigate the Efficacy of Tradipitant in Subjects Affected by Motion Sickness

NCT04196933Not ApplicableWithdrawn

Analysis of Vestibular Compensation Following Clinical Intervention for Vestibular Schwannoma

NCT05903924Phase 3CompletedPrimary

Motion Serifos: A Study to Investigate the Efficacy of Tradipitant in Participants Affected by Motion Sickness

NCT04327661Phase 3CompletedPrimary

Motion Syros: A Study to Investigate the Efficacy of Tradipitant in Subjects Affected by Motion Sickness

NCT06128707CompletedPrimary

Vestibulo-Ocular Reflex Function in Individuals With Chronic Motion Sensitivity Cross-Sectional Study

NCT05886660Phase 2Recruiting

Combination of Intranasal Scopolamine and Sensory Augmentation to Mitigate G-transition Induced Motion Sickness and Enhance Sensorimotor Performance

NCT06232785Phase 4CompletedPrimary

Gynecologic Endoscopic Surgery of Female Motion Sickness Patients

NCT06056622Not ApplicableCompletedPrimary

Motion Sickness Rehabilitation for Virtual Reality

NCT04420949Not ApplicableCompleted

Sensory Training for Visual Motion Sickness

NCT03988530Phase 3CompletedPrimary

Prevention and Treatment of Nausea Associated With Motion Sickness in Senior Subjects

NCT05548270Phase 3CompletedPrimary

Efficacy and Safety of DPI-386 Nasal Gel for the Prevention of Nausea and Vomiting Associated With Motion

NCT05628220Not ApplicableUnknownPrimary

Motion Sickness Desensitization Using VR

Scroll to load more

Research Network

Activity Timeline